YOLFTbeta
Enanta Pharmaceuticals Inc

Enanta Pharmaceuticals Inc

ENTA · NASDAQ · Healthcare / Biotechnology

10.99USD-0.21 (-1.87%)

Price History

Full chart

Market Stats

Previous Close11.20
Open11.19
Day Range10.51 – 11.66
52-Week Range7.05 – 17.15
Volume127.69K
Market Cap349.50M
P/E (TTM)0.00
Forward P/E44.05
EPS-2.43
Dividend Yield0.00%
Beta0.94
50-Day Avg13.17
200-Day Avg13.55

About

Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for virology and immunology indications. The company's product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; zelicapavir and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; EDP-978 for chronic spontaneous urticaria (CSU); Glecaprevir, antiviral protease inhibitors for the treatment of chronic infection with hepatitis C virus or HCV; and EPS-3903 for the treatment of atopic dermatitis. It has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. The company was incorporated in 1995 and is headquartered in Watertown, Massachusetts.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEODr. Jay R. Luly Ph.D.
  • Employees120
  • Headquarters4 Kingsbury Avenue, Watertown, MA, United States, 02472, USA
  • Websitehttps://www.enanta.com

Leadership

  • Dr. Jay R. Luly Ph.D.President, CEO & Director · b. 1956
  • Dr. Yat Sun Or Ph.D.Chief Scientific Officer · b. 1952
  • Dr. Scott T. Rottinghaus M.D.Chief Medical Officer · b. 1974
  • Mr. Harry R. Trout IIIVP of Finance & Interim Principal Financial Officer · b. 1969
  • Ms. Kathleen S. Capps CPAExecutive Director of Accounting, Controller & Interim Principal Accounting Officer · b. 1985
  • Ms. Jennifer VieraExecutive Director of Investor Relations & Corporate Communications
  • Mr. Matthew P. Kowalsky J.D.Chief Legal Officer & Corporate Secretary · b. 1973
  • Mr. Nathaniel S. Gardiner J.D.Consultant · b. 1954
  • Ms. Tara Lynn Kieffer Ph.D.Chief Product Strategy Officer · b. 1978
  • Mr. Brendan LuuChief Business Officer · b. 1975

Financials

Income Statement

Currency: USD2010-09-302011-09-302012-09-302013-09-302014-09-302015-09-302016-09-302017-09-302018-09-302019-09-302020-09-302021-09-302022-09-302023-09-302024-09-302025-09-30
Total Revenue22.76M41.88M41.71M32.05M47.74M160.88M88.27M102.81M206.63M205.20M122.47M97.07M86.16M79.20M67.64M65.32M
Growth (%)-+83.99%-0.42%-23.15%+48.94%+236.98%-45.13%+16.48%+100.97%-0.69%-40.31%-20.74%-11.24%-8.07%-14.61%-3.42%
Cost of Revenue-16.08M20.25M22.80M28.76M36.09M55.77M76.06M115.78M---2.97M2.37M-4.59M
Gross Profit22.76M41.88M41.71M32.05M47.74M160.88M88.27M102.81M206.63M205.20M122.47M97.07M86.16M79.20M67.64M60.74M
Gross Margin100.00%100.00%100.00%100.00%100.00%100.00%100.00%100.00%100.00%100.00%100.00%100.00%100.00%100.00%100.00%92.98%
Operating Expense15.82M16.58M20.42M23.02M28.76M36.73M57.43M78.20M118.30M168.46M164.11M206.65M210.00M216.41M189.33M146.09M
Operating Income6.94M25.30M21.29M9.03M18.98M124.15M30.84M24.61M88.33M36.74M-41.64M-109.57M-123.84M-137.21M-121.69M-85.35M
Operating Margin30.50%60.41%51.05%28.17%39.77%77.17%34.94%23.94%42.75%17.90%-34.00%-112.88%-143.74%-173.23%-179.92%-130.65%
EBITDA8.30M26.97M21.57M9.25M19.34M124.79M32.50M26.75M90.85M40.00M-37.99M-106.24M-119.22M-123.48M-104.51M-70.78M
EBITDA Margin36.46%64.40%51.72%28.86%40.50%77.57%36.82%26.02%43.97%19.49%-31.02%-109.44%-138.36%-155.90%-154.52%-108.35%
Net Income7.90M23.31M21.40M9.63M34.44M78.99M21.67M17.71M71.96M46.38M-36.17M-79.00M-121.75M-133.82M-116.05M-81.89M
Net Income Margin34.72%55.66%51.31%30.03%72.14%49.10%24.55%17.23%34.82%22.60%-29.53%-81.38%-141.31%-168.95%-171.58%-125.36%
R&D9.72M11.55M15.12M16.84M18.74M23.19M40.46M57.45M94.86M142.21M136.76M174.11M164.52M163.52M131.48M106.74M
R&D as % of Total Revenue42.68%27.57%36.24%52.54%39.25%14.41%45.84%55.88%45.91%69.31%111.66%179.36%190.95%206.46%194.39%163.40%
Interest Expense03.16M031.00K18.00K8.00K45.00K40.00K4.85M8.82M10.26M5.33M1.57M5.15M10.94M7.68M
Interest Expense % of Total Revenue0.00%7.55%0.00%0.10%0.04%0.00%0.05%0.04%2.35%4.30%8.38%5.49%1.83%6.50%16.18%11.76%

Balance Sheet

Currency: USD2010-09-302011-09-302012-09-302013-09-302014-09-302015-09-302016-09-302017-09-302018-09-302019-09-302020-09-302021-09-302022-09-302023-09-302024-09-302025-09-30
Total Assets-26.10M52.16M116.97M155.41M246.01M281.28M326.64M414.23M489.83M490.79M440.86M380.59M462.27M376.65M280.73M
Total Liabilities-158.06M8.23M6.50M6.76M9.86M11.34M24.96M20.55M27.34M35.21M41.43M59.26M245.54M247.84M216.01M
Total Equity--131.96M43.93M110.47M148.65M236.16M269.94M301.68M393.68M462.49M455.58M399.43M321.33M216.74M128.81M64.72M
Cash-6.84M10.51M8.86M30.70M21.73M16.58M65.67M63.90M51.23M87.13M57.21M43.99M85.39M37.23M32.30M
Total Debt----200.00K761.00K690.00K1.22M293.00K200.00K9.58M6.83M26.69M26.51M226.06M201.06M
Net Debt--6.84M-10.51M-8.86M-30.50M-21.13M-16.05M-65.22M-63.61M-51.03M-77.55M-50.37M-17.31M-58.88M188.82M168.76M

Cash Flow

Currency: USD2010-09-302011-09-302012-09-302013-09-302014-09-302015-09-302016-09-302017-09-302018-09-302019-09-302020-09-302021-09-302022-09-302023-09-302024-09-302025-09-30
Operating Cash Flow-10.18M24.02M22.62M10.65M20.18M76.67M35.81M52.65M29.22M71.42M7.09M-70.00M-84.78M-103.15M-78.76M-19.27M
Investing Cash Flow1.66M-17.68M-18.04M-69.22M497.00K-88.19M-43.66M-4.57M-35.40M-86.66M19.83M36.99M54.90M-53.58M58.23M40.35M
Financing Cash Flow8.00K34.00K-909.00K56.91M1.16M2.54M2.71M1.02M4.41M2.57M8.98M3.08M20.03M198.13M-27.63M-26.62M
Capital Expenditure37.00K445.00K252.00K606.00K1.03M2.34M4.74M2.51M2.98M5.42M1.45M750.00K2.13M9.06M17.95M12.90M
Free Cash Flow-10.21M23.57M22.37M10.05M19.15M74.34M31.07M50.15M26.24M66.00M5.64M-70.75M-86.91M-112.21M-96.71M-32.17M
Dividends Paid---0000002.66M------
FCF to OCF100.36%98.15%98.89%94.31%94.91%96.95%86.77%95.24%89.80%92.42%79.61%101.07%102.51%108.78%122.79%166.92%
Dividend Paid to FCF---0.00%0.00%0.00%0.00%0.00%0.00%4.03%------

Earnings

Report DateMay 8, 2013Aug 12, 2013Nov 25, 2013Feb 13, 2014May 12, 2014Aug 11, 2014Nov 24, 2014Feb 5, 2015May 7, 2015Aug 6, 2015Nov 23, 2015Feb 8, 2016May 9, 2016Aug 8, 2016Nov 21, 2016Feb 8, 2017May 8, 2017Aug 7, 2017Nov 20, 2017Feb 7, 2018May 8, 2018Aug 7, 2018Nov 26, 2018Feb 6, 2019May 7, 2019Aug 6, 2019Nov 21, 2019Feb 6, 2020May 6, 2020Aug 4, 2020Nov 23, 2020Feb 8, 2021May 6, 2021Aug 5, 2021Nov 22, 2021Feb 8, 2022May 9, 2022Aug 8, 2022Nov 21, 2022Feb 7, 2023May 8, 2023Aug 7, 2023Nov 20, 2023Feb 7, 2024May 6, 2024Aug 5, 2024Nov 25, 2024Feb 10, 2025May 12, 2025Aug 11, 2025Nov 17, 2025Feb 9, 2026May 11, 2026Aug 10, 2026Nov 16, 2026
EPS Estimate-0.33-0.31-0.31-0.290.221.71-0.333.821.740.160.241.130.14-0.09-0.18-0.18-0.38-0.482.130.270.250.901.191.29-0.050.170.560.60-0.72-0.96-0.97-0.77-0.97-1.29-1.19-1.11-1.41-1.39-1.35-1.60-1.93-2.19-2.21-1.23-1.40-1.41-0.92-1.35-1.14-0.88-1.01-0.88-0.57-0.37-0.82
EPS Actual-1.81-0.23-0.25-0.30-0.281.82-0.272.181.490.130.291.36-0.09-0.06-0.09-0.26-0.28-0.441.860.400.610.971.301.250.200.330.440.65-0.30-0.71-1.46-0.41-1.09-1.19-1.22-1.48-1.63-1.53-1.27-1.39-1.79-1.86-1.33-1.58-1.47-1.07-1.36-1.05-1.06-0.85-0.87-0.42-0.45-0.67-
Surprise-448.48%25.81%19.35%-3.45%-227.27%6.43%18.18%-42.93%-14.37%-18.75%20.83%20.35%-164.29%33.33%50.00%-44.44%26.32%8.33%-12.68%48.15%144.00%7.78%9.24%-3.10%500.00%94.12%-21.43%8.33%58.33%26.04%-50.52%46.75%-12.37%7.75%-2.52%-33.33%-15.60%-10.07%5.93%13.13%7.25%15.07%39.82%-28.46%-5.00%24.11%-47.83%22.22%7.02%3.41%13.86%52.27%21.05%-81.08%-
TimingPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hours

Key Statistics & Ratios

Market Cap349.50M
Enterprise Value214.20M
Trailing P/E0.00
Forward P/E44.05
PEG Ratio0.00
Price / Sales5.36
Price / Book3.44
EPS-2.43
Book Value3.47
Revenue (TTM)65.26M
Gross Profit (TTM)65.26M
EBITDA-53.82M
Profit Margin-96.89%
Operating Margin-120.04%
Return on Equity-70.12%
Return on Assets-12.28%
Shares Outstanding29.13M
Shares Float22.52M
Beta0.94
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Analyst Ratings

Buy
Based on 6 analystsTarget 21.83
  • Strong Buy
    2
  • Buy
    1
  • Hold
    2
  • Sell
    1

Ownership Breakdown

Institutions
94.37%
Insiders
4.67%
Retail / Other
0.96%

Top Institutional Holders

  • HHG PLC
    3.78M12.99%
  • BlackRock Inc
    3.10M10.66%
  • Farallon Capital Management, L.L.C.
    2.87M9.86%
  • Krensavage Asset Management, LLC
    2.87M9.84%
  • Deep Track Capital, LP
    1.44M4.96%
  • Vanguard Capital Management, LLC
    1.18M4.04%
  • Spruce Street Capital LP
    1.09M3.74%
  • Vanguard Portfolio Management, LLC
    948.90K3.26%
  • Acadian Asset Management LLC
    880.02K3.02%
  • Geode Capital Management, LLC
    725.06K2.49%
  • Renaissance Technologies Corp
    665.26K2.28%
  • Millennium Management LLC
    643.97K2.21%
  • State Street Corp
    562.11K1.93%
  • Hillsdale Investment Management Inc.
    468.00K1.61%
  • AQR Capital Management LLC
    313.16K1.08%
  • Morgan Stanley - Brokerage Accounts
    309.51K1.06%

Top Fund Holders

  • Vanguard MStar Total Stk Mkt Idx Invest
    877.12K3.01%
  • iShares Russell 2000 ETF
    724.86K2.49%
  • BlackRock Health Sciences Opps Inv A
    492.00K1.69%
  • Hillsdale US Small Cap Eq Fund Srs A U$
    352.70K1.21%